Bioequivalency Study of Ibuprofen 200 mg and Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's Under Fasting Conditions

NCT ID: NCT01131780

Last Updated: 2010-06-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-10-31
• Study Completion Date: 2004-11-30

Brief Summary

The purpose of this study is to assess the bioequivalence of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg under fasting conditions.

Detailed Description

This study assess the bioequivalence of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's and Advil® Cold and Sinus Caplets of Wyeth Consumer Healthcare in healthy human adult subjects with the single oral administration under fasting conditions with a washout period of 7 days.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ibuprofen + Psuedoephedrine Hydrochloride

Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets

Group Type: EXPERIMENTAL

Ibuprofen + Pseudoephedrine Hydrochloride

Intervention Type: DRUG

Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets

Advil® Cold and Sinus

Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare

Group Type: ACTIVE_COMPARATOR

Ibuprofen + Pseudoephedrine Hydrochloride

Intervention Type: DRUG

Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets

Interventions

Ibuprofen + Pseudoephedrine Hydrochloride

Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets

Intervention Type: DRUG

Other Intervention Names

Advil® Cold and Sinus

Eligibility Criteria

Inclusion Criteria

• Healthy human subjects between 18-50 years of age (inclusive), weighing as per the standard height and weight chart of Life Insurance Corporation of India (II Underweight and Overweight Min. & Max. Chart)
• Subjects who have no evidence of underlying disease during screening medical history and whose physical examination is performed within 21 days to commencement of the study.
• Subjects whose screening laboratory values are within normal limits or considered by the physician/Principal Investigator to be of no clinical significance.
• Informed consent given in written form according to section 10.3 of the protocol.
• Female Subjects:

1. of child bearing potential practicing an acceptable method of birth control for the duration of study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.

2. postmenopausal for at least 1 year.

3. surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject.

Exclusion Criteria

1. History or presence of significant:

• Cardiovascular, pulmonary, hepatic, renal hematological; gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
• Alcohol dependence, alcohol abuse or drug abuse within past one year.
• Moderate to heavy smoking (> 10 cigarettes/day) or on assumption of tobacco products.
• History of difficulty in swallowing.
• Clinically significant illness within 4 weeks before the start of the study
• Asthma, urticaria or other allergic type reactions after taking any medication.

2. Subjects who, through completion of the study, would have donated in excess of:

• 500ml of blood in 14 days, or
• 500 - 800 m l of blood in 14 days (unless approved by the Principal Investigator)
• 1000 ml of blood in 90 days
• 1250 ml of blood in 120 days
• 1500 ml of blood in 180 days
• 2000 ml of blood in 270 days
• 2500 ml of blood in 1 year

3. Participation in another clinical trial within the preceding 28 days of study start.

4. Subjects who have:

• Systolic blood pressure less than 90 mm of Hg and more than 150 mm of Hg
• Diastolic blood pressure less than 60 m of Hg and more than 95 mm of Hg. Minor deviations (1-3 mm Hg) at check-in may be acceptable at the discretion of the physician/investigator
• Pulse rate below 50/min. and above 105/min.

5. Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Dr. Reddy's Laboratories Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Dr. Reddy's Laboratories Limited

Principal Investigators

Vijayanthi G, MBBS, MD

Role: PRINCIPAL_INVESTIGATOR

Lotus Labs Pvt. Ltd.

Locations

Lotus Labs Pvt. Ltd.

Bangalore, Karnataka, India

Countries

India

Other Identifiers

432/04

Identifier Type: -

Identifier Source: org_study_id